Stock of the Day

August 31, 2023

SCYNEXIS (SCYX)

$5.17
-$0.06 (-1.1%)
Market Cap: $51.44M

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Today's Trend

SCYNEXIS, Inc. (SCYX) — Shares have moved lower following mixed analyst model changes and company updates. Near-term earnings guidance from Brookline Capital Acquisition was cut sharply for FY2026, offset by upward revisions for later years and an ongoing clinical-stage development program. Trading volume is below average, suggesting limited conviction behind today’s move.

  • Brookline Capital Acquisition raised multi‑year EPS forecasts for FY2027–FY2029 (FY2027: ($0.20) vs prior ($0.48); FY2028: ($0.29) vs ($0.30); FY2029: ($0.62) vs ($0.64)) and maintained a "Buy" rating — this signals improved medium‑term profitability expectations and analyst conviction. MarketBeat SCYX Coverage
  • SCYNEXIS announced first participants dosed in the Phase 1 IV trial of SCY‑247, its second‑generation triterpenoid antifungal candidate — clinical progress can drive long‑term value if the program advances. InsiderMonkey Article
  • Brookline’s long‑range view includes a FY2030 EPS forecast of $0.46, implying a path to profitability several years out — bullish if achieved but distant and dependent on clinical/regulatory success. MarketBeat SCYX Coverage
  • Brookline sharply reduced FY2026 EPS from $1.03 to ($0.34), a material downward revision that suggests near‑term financial weakness or modeling changes — this is a clear negative catalyst for sentiment. MarketBeat SCYX Coverage
  • Analyst quarterly estimates from Brookline show continued quarterly losses across 2026 (Q1–Q3 at ($0.10), Q4 at ($0.05)), reinforcing the expectation of near‑term negative earnings and potential dilution or funding risk. MarketBeat SCYX Coverage

Investor takeaway: near‑term weakness in FY2026 guidance and ongoing quarterly losses are weighing on the stock, while analyst upgrades for later years and the SCY‑247 Phase 1 dosing support longer‑term upside if clinical development succeeds. Short‑term direction will likely hinge on upcoming clinical readouts, cash‑burn/funding updates, and whether further analyst/model revisions confirm the path to FY2030 profitability.

← Previous Stock of the DayNext Stock of the Day →

Recent News